SCHEMBL2559322

SCHEMBL2559322

O=Cc1ccc(-c2cc(C(=O)O)ccc2Cl)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 7/20 0.60
TDP1 Q9NUW8 4/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 8/20 0.59
ALDH1A1 P00352 3/20 0.57
STAT3 P40763 1/20 0.57
NPC1 O15118 3/20 0.56
GAA P10253 3/20 0.56
RAB9A P51151 2/20 0.56
MCL1 Q07820 2/20 0.56
MAPT P10636 5/20 0.56
RECQL P46063 1/20 0.56
LMNA P02545 1/20 0.52
SLC1A3 P43003 3/20 0.50
PKM P14618 2/20 0.48
ITGB2 P05107 1/20 0.48
ITGAM P11215 1/20 0.48
NPSR1 Q6W5P4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2557304 0.82 KDM4E (0.65) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL4697667 0.80 HPGD (0.65) POLBTDP1MEN1KMT2AKDM4E
SCHEMBL18920689 0.79 KDM4E (0.60) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL2560093 0.79 PPM1G (0.65) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL14363094 0.79 L3MBTL1 (0.50) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL14426477 0.79 KMT2A (0.68) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL3362325 0.75 MEN1 (0.82) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL3362327 0.75 MEN1 (0.82) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL29665101 0.75 MEN1 (0.82) POLBTDP1L3MBTL1MEN1KMT2A
SCHEMBL12812715 0.75 MEN1 (0.82) POLBTDP1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 POLB 2065/4885TDP1 2838/4885L3MBTL1 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.